Advertisement

Der hämatologisch-onkologische Intensivpatient

Therapie ohne Grenzen
  • M. KochanekEmail author
  • A. Shimabukuro-Vornhagen
  • B. Böll
Leitthema
  • 23 Downloads

Zusammenfassung

Die Behandlungsmöglichkeiten und Erfolge bei Patienten mit einer Krebserkrankung sind in den letzten Jahren deutlicher, mehr und besser geworden. Vieler dieser Patienten benötigen aber aufgrund von Komorbiditäten, therapieassoziierten Komplikationen oder im Rahmen schwerer Infektionen einen Intensivaufenthalt. Dabei sind die Grenzen zwischen dem intensivmedizinisch Machbaren und Sinnvollen schwer zu ziehen. Über die letzten Jahre ist zunehmend ein Problembewusstsein für diese Krebspatienten auf Intensivstation entstanden und eine Diskussion darüber in Gang gekommen. Dieser Beitrag soll eine Diskussionsgrundlage und auch mögliche Lösungsstrategien anbieten.

Schlüsselwörter

Intensivmedizin Krebs Hämatologie Medizinische Onkologie Triage  

Hematological–oncological intensive care patients

Treatment without borders

Abstract

The number of treatment options and success of treating patients with cancer have both significantly increased in recent years. However, many of these patients require intensive care due to comorbidities, treatment-associated complications, or severe infections. At the same time, the boundaries between what is feasible and sensible are difficult to draw. Over the past few years, awareness of the problems these cancer patients may have in the intensive care unit has increased and discussions have begun. This article intends to offer a discussion basis and also possible solution strategies.

Keywords

Intensive care Cancer Hematology Medical oncology Triage 

Notes

Einhaltung ethischer Richtlinien

Interessenkonflikt

M. Kochanek, A. Shimabukuro-Vornhagen und B. Böll geben an, dass kein Interessenkonflikt besteht.

Dieser Beitrag beinhaltet keine von den Autoren durchgeführten Studien an Menschen oder Tieren.

Literatur

  1. 1.
    ABIM Foundation (2019) Choosing Wisely®. http://www.choosingwisely.org/. Zugegriffen: 15. Januar 2019
  2. 2.
    Azoulay E, Kouatchet A, Jaber S et al (2012) Noninvasive mechanical ventilation in patients having declined tracheal intubation. Intensive Care Med 39:292–301.  https://doi.org/10.1007/s00134-012-2746-2 CrossRefPubMedGoogle Scholar
  3. 3.
    Azoulay E, Mokart D, Pène F et al (2013) Outcomes of critically ill patients with hematologic malignancies: Prospective multicenter data from France and Belgium—a groupe de recherche respiratoire en réanimation onco-hématologique study. J Clin Oncol 31:2810–2818.  https://doi.org/10.1200/JCO.2012.47.2365 CrossRefPubMedGoogle Scholar
  4. 4.
    Azoulay E, Recher C, Alberti C et al (1999) Changing use of intensive care for hematological patients: The example of multiple myeloma. Intensive Care Med 25:1395–1401CrossRefGoogle Scholar
  5. 5.
    Azoulay E, Soares M, Darmon M et al (2011) Intensive care of the cancer patient: Recent achievements and remaining challenges. Ann Intensive Care 1(1):5.  https://doi.org/10.1186/2110-5820-1-5 CrossRefPubMedPubMedCentralGoogle Scholar
  6. 6.
    Centers for Disease Control and Prevention (CDC) (2011) Cancer survivors—United States, 2007. MMWR Morb Mortal Wkly Rep 60:269–272Google Scholar
  7. 7.
    Crawford SW, Petersen FB (1992) Long-term survival from respiratory failure after marrow transplantation for malignancy. Am Rev Respir Dis 145:510–514.  https://doi.org/10.1164/ajrccm/145.3.510 CrossRefPubMedGoogle Scholar
  8. 8.
    Deutsche Gesellschaft für Innere Medizin (2018) Klug entscheiden. https://www.klug-entscheiden.com/empfehlungen/uebersicht/. Zugegriffen: 15. Januar 2019
  9. 9.
    Griesenauer RH, Kinch MS (2017) 2016 in review: FDA approvals of new molecular entities. Drug Discov Today 22:1593–1597.  https://doi.org/10.1016/j.drudis.2017.06.011 CrossRefPubMedGoogle Scholar
  10. 10.
    Kiehl MG, Beutel G, Böll B et al (2018) Consensus statement for cancer patients requiring intensive care support. Ann Hematol 97:1271–1282.  https://doi.org/10.1007/s00277-018-3312-y CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Zentrum für Krebsregisterdaten, Gesellschaft der epidemiologischen Krebsregister in Deutschland e.V. (2017) Krebs in Deutschland für 2013/2014, 11. Aufl. Robert-Koch-Institut, BerlinGoogle Scholar
  12. 12.
    Lanken PN, Terry PB, DeLisser HM et al (2008) An official American thoracic society clinical policy statement: Palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 177:912–927.  https://doi.org/10.1164/rccm.200605-587ST CrossRefPubMedGoogle Scholar
  13. 13.
    Legrand M, Max A, Peigne V et al (2012) Survival in neutropenic patients with severe sepsis or septic shock. Crit Care Med 40:43–49.  https://doi.org/10.1097/CCM.0b013e31822b50c2 CrossRefPubMedGoogle Scholar
  14. 14.
    Massion PB, Dive AM, Doyen C et al (2002) Prognosis of hematologic malignancies does not predict intensive care unit mortality. Crit Care Med 30:2260–2270.  https://doi.org/10.1097/01.CCM.0000030456.11264.EF CrossRefPubMedGoogle Scholar
  15. 15.
    Miller KD, Siegel RL, Lin CC et al (2016) Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin 66:271–289.  https://doi.org/10.3322/caac.21349 CrossRefPubMedGoogle Scholar
  16. 16.
    Neitzke G, Boll B, Burchardi H et al (2017) Documentation of decisions to withhold or withdraw life-sustaining therapies: Recommendation of the ethics section of the German Interdisciplinary Association of Critical Care and Emergency Medicine (DIVI) in collaboration with the ethics section of the German Society for Medical Intensive Care and Emergency Medicine (DGIIN). Med Klin Intensivmed Notfmed 112:527–530.  https://doi.org/10.1007/s00063-017-0321-x CrossRefPubMedGoogle Scholar
  17. 17.
    Oeyen SG, Benoit DD, Annemans L et al (2013) Long-term outcomes and quality of life in critically ill patients with hematological or solid malignancies: a single center study. Intensive Care Med 39:889–898.  https://doi.org/10.1007/s00134-012-2791-x CrossRefPubMedGoogle Scholar
  18. 18.
    Pène F, Percheron S, Lemiale V et al (2008) Temporal changes in management and outcome of septic shock in patients with malignancies in the intensive care unit. Crit Care Med 36:690–696.  https://doi.org/10.1097/CCM.0B013E318165314B CrossRefPubMedGoogle Scholar
  19. 19.
    Puxty K, McLoone P, Quasim T et al (2014) Survival in solid cancer patients following intensive care unit admission. Intensive Care Med 40:1409–1428.  https://doi.org/10.1007/s00134-014-3471-9 CrossRefPubMedGoogle Scholar
  20. 20.
    Schellongowski P (2013) Cancer patients in the intensive care unit. Med Klin Intensivmed Notfmed 108:203–208.  https://doi.org/10.1007/s00063-012-0177-z CrossRefPubMedGoogle Scholar
  21. 21.
    Schellongowski P, Staudinger T, Kundi M et al (2011) Prognostic factors for intensive care unit admission, intensive care outcome, and post-intensive care survival in patients with de novo acute myeloid leukemia: A single center experience. Haematologica 96:231–237.  https://doi.org/10.3324/haematol.2010.031583 CrossRefPubMedGoogle Scholar
  22. 22.
    Schuster DP (1992) Everything that should be done—not everything that can be done. Am Rev Respir Dis 145:508–509.  https://doi.org/10.1164/ajrccm/145.3.508 CrossRefPubMedGoogle Scholar
  23. 23.
    SEER Datenbank USA (2008) Überlebensdaten USA SEER Register. NCIGoogle Scholar
  24. 24.
    Siegel RL, Jemal A, Wender RC et al (2018) An assessment of progress in cancer control: An assessment of progress in cancer control. CA Cancer J Clin 68:329–339.  https://doi.org/10.3322/caac.21460 CrossRefPubMedGoogle Scholar
  25. 25.
    Staudinger T, Stoiser B, Müllner M et al (2000) Outcome and prognostic factors in critically ill cancer patients admitted to the intensive care unit. Crit Care Med 28:1322–1328.  https://doi.org/10.1097/00003246-200005000-00011 CrossRefPubMedGoogle Scholar
  26. 26.
    Vivot A, Jacot J, Zeitoun J‑D et al (2017) Clinical benefit, price and approval characteristics of FDA-approved new drugs for treating advanced solid cancer, 2000–2015. Ann Oncol 28:1111–1116.  https://doi.org/10.1093/annonc/mdx053 CrossRefPubMedGoogle Scholar
  27. 27.
    van Vliet M, van den Boogaard M, Donnelly JP et al (2014) Long-term health related quality of life following intensive care during treatment for haematological malignancies. PLoS ONE 9:e87779.  https://doi.org/10.1371/journal.pone.0087779 CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    Vogelzang NJ, Benowitz SI, Adams S et al (2012) Clinical cancer advances 2011: Annual report on progress against cancer from the American Society of Clinical Oncology. J Clin Oncol 30:88–109.  https://doi.org/10.1200/JCO.2011.40.1919 CrossRefPubMedGoogle Scholar
  29. 29.
    de Vries VA, Müller MCA, Arbous MS et al (2018) Long-term outcome of patients with a hematologic malignancy and multiple organ failure admitted at the intensive care. Crit Care Med 1.  https://doi.org/10.1097/CCM.0000000000003526 CrossRefGoogle Scholar
  30. 30.
    Wohlfarth P, Carlström A, Staudinger T et al (2016) Incidence of intensive care unit admission, outcome and post intensive care survival in patients with diffuse large B‑cell lymphoma. Leuk Lymphoma 57:1831–1838.  https://doi.org/10.3109/10428194.2015.1106537 CrossRefPubMedGoogle Scholar
  31. 31.
    Zimmerman JE, Kramer AA, Knaus WA (2013) Changes in hospital mortality for United States intensive care unit admissions from 1988 to 2012. Crit Care 17:R81.  https://doi.org/10.1186/cc12695 CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2019

Authors and Affiliations

  • M. Kochanek
    • 1
    • 2
    • 3
    Email author
  • A. Shimabukuro-Vornhagen
    • 1
    • 2
  • B. Böll
    • 1
    • 2
  1. 1.Klinik I für Innere Medizin, Schwerpunkt Internistische IntensivmedizinKlinikum der Universität zu KölnKölnDeutschland
  2. 2.Arbeitsgruppe Intensive Care in Hematologic and Oncologic Patients (iCHOP) der DGHO/DGIINKöln-BonnDeutschland
  3. 3.Centrum für Integrierte Onkologie Köln-BonnKöln-BonnDeutschland

Personalised recommendations